Fortrea
Darby Thomas is a highly experienced scientific leader with a focus on gene therapies, rare diseases, and advanced therapies in pediatrics. Currently serving as the Scientific Director at Fortrea since May 2023, Thomas has held significant roles including Director of Enterprise Cell and Gene Therapy at Labcorp Drug Development and VP of Early Development at Sio Gene Therapies. Previous positions at StrideBio, Precigen Inc., and Intrexon Corporation encompassed key responsibilities in program and project management, alliance management, and preclinical development for various gene therapy initiatives. Thomas's early career included a postdoctoral fellowship at the University of Pennsylvania and formative roles at Applied Genetic Technologies Corporation. Educational credentials include a Ph.D. in Virology from Baylor College of Medicine and a BS with Honors in Biology from the University of North Carolina at Chapel Hill.
This person is not in any teams
This person is not in any offices
Fortrea
11 followers
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of approximately 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com.